Compound
← Compound
Official website →
MRKMerck & Co., Inc.
Quotes delayed by up to 15 minutes · informational, not investment advice
Escopo e origem dos dados
- Ativo
- MRK
- Moeda das demonstrações
- USD
- Último período anual nesta tabela
- 2025-12-31
- Fonte das demonstrações
- SEC EDGAR
Data de demonstração não é horário de cotação. Dado ausente não é zero. A cobertura varia por ativo e fonte; confira o documento original antes de interpretar um número.
Fontes e metodologiaAbout the company
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunolog…
IndustryDrug Manufacturers - General
Smart calendar
Organizing upcoming events...
Key metrics
What the market pays
P/E
Price divided by trailing 12-month earnings
118.65×
P/B
Price divided by book value
8.81×
EV/EBITDA
Enterprise value divided by operating cash generation
30.07×
EV/Revenue
Enterprise value divided by revenue
6.27×
What the company earns
ROE
Return on shareholders’ equity
6.6%
ROA
Return on all assets
2.4%
Gross margin
What remains after product costs
75.4%
Operating margin
What remains after operating the business
16.7%
Net margin
How much of each revenue unit becomes profit
4.8%
What it owes
Debt / Equity
Debt for each unit of shareholders’ equity
1.29
Total debt
Sum of borrowings
$53.91B
Cash
Cash available to cover it
$6.85B
Current ratio
Short-term assets divided by short-term liabilities
1.32
Free cash flow
Cash left after investing
$4.48B
Risk and growth
Beta
Moves more (>1) or less (<1) than the market
0.23
Revenue growth
Compared with the same period a year earlier
5.1%
Earnings growth
Compared with the same period a year earlier
-130.2%
Dividend yield
Trailing 12-month distributions divided by price
2.3%
Market data provider figures for the latest published period. Informational, not investment advice.
Financial statements(USD)
Income statement
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Receita | 59.28B | 60.12B | 64.17B | 65.01B |
| Custo dos produtos | -17.41B | -16.13B | -15.19B | -16.38B |
| Despesas com vendas e administrativas | -10.04B | -10.5B | -10.82B | -10.73B |
| Pesquisa e desenvolvimento | -13.55B |
News about MRK
Yahoo Finance · 19 hours ago
Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher
Seeking Alpha · 22 hours ago
4 stocks to watch on Monday: HPQ, PFE, MRK, and MRVL
The supplied excerpt provides a watchlist context rather than company-specific analysis for PFE, MRK, or MRVL. The broader market backdrop was positive for index futures, but the article also identifies geopolitical developments that could affect sentiment.
Seeking Alpha · 23 hours ago
Merck secures Japanese approval for subcutaneous Keytruda
Yahoo Finance · 2 days ago
Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story?
The article presents Merck as having a less diversified current income base than Amgen: Keytruda remains a major contributor, while the company is relying on more than 20 new products and a stated $70 billion commercial opportunity to offset eventual loss of exclusivity. Its dividend increased from $0.81 to $0.85 per share from 2025 to 2026, described as a smaller step-up than Amgen's. The comparison therefore frames Merck's dividend durability as dependent on pipeline execution, while Amgen is selected for its broader product base and faster dividend increases.
Follow MRK and get agent analysis of what is moving the stock.
Open Compound